AI assistant
FD Technologies Ltd. — M&A Activity 2024
Dec 3, 2024
6234_tar_2024-12-03_ccd0bbef-cca3-47c6-8bf0-dd1b36fc2997.html
M&A Activity
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information ![]()
RNS Number : 4889O
FD Technologies PLC
03 December 2024
FD Technologies plc
("FD Technologies" or the "Company")
3rd December 2024
COMPLETION OF Divestment of First Derivative
FD Technologies (AIM: FDP.L, Euronext Growth: FDP.I) is pleased to announce that the sale of First Derivative to EPAM Systems, Inc. has completed, pursuant to the terms previously announced by the Company on 7 October 2024.
For further information, please contact:
FD Technologies plc
Seamus Keating, Chief Executive Officer
Ryan Preston, Chief Financial Officer
Derek Brown, Head of Investor Relations
+44(0)28 3025 2242
www.fdtechnologies.com
Investec Bank plc
(Nominated Adviser and Broker)
Carlton Nelson
Virginia Bull
+44 (0)20 7597 5970
FTI Consulting
Matt Dixon
Dwight Burden
Victoria Caton
+44 (0)20 3727 1000
About KX
KX is on a mission to make AI a commercial reality for the many by addressing data challenges that impede deployment at scale. By simultaneously ingesting and analysing high volumes of historical and real-time data, KX's AI-ready analytical database enables organizations to unlock the full value of their data to accelerate innovation and make faster, more confident decisions.
KX is the world's most performant, cost-effective and energy-efficient analytical database, delivering advanced data algorithms, insights and analytics at unmatched scale and speed. KX is trusted by the world's top investment banks, Aerospace and Defence, high-tech manufacturing and health and life sciences organizations and operates across North America, Europe, and Asia Pacific.
For further information, please visit www.fdtechnologies.com and www.kx.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DISFSFFWEELSESE